ERNA
Ernexa Therapeutics Inc.
Next earnings Aug 11, 2026 · consensus $-3.37 EPS
$6.97
▼ -5.81%$6.97▼ -88.38%
over 1Y
L $3.69EODHDH $60.00
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-5.8%
1W+18.3%
1M-37.4%
3M+38.0%
YTD-76.0%
1Y-88.4%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 6 analysts
Sell
Revenue grew 755.9% YoY; but unprofitable (net margin -2419.9%).
Revenue (FY2024) $582K · FY2024
Ernexa Therapeutics Inc. shows $582K in FY2024 revenue (+755.9% YoY), a -2419.9% net margin, and -586.6% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | $0.00 | $68.0K | $582K | — |
| Gross profit | — | $0.00 | -$168K | $486K | — |
| Operating income | -$114M | -$33.2M | -$21.1M | -$15.7M | -$9.32M |
| Net income | -$123M | -$24.6M | -$21.7M | -$44.5M | -$14.1M |
| Diluted EPS | -$56.61 | -$8.06 | -$4.08 | -$48.96 | -$2.24 |
| Net margin | — | — | -31864.7% | -7652.7% | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$203M
EV / EBITDA—
EV / Sales349.4
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-6.9%
FCF yield-3.5%
Quality & risk
ROIC (est.)-166.1%
Free cash flow-$7.05M
Total debt$2.03M
Net cash-$148K
Altman Z-Score-28.60 distress
Piotroski F-Score6/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY-44.2%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — delisting notice (2026-03-20). Worth a closer look.
- 8-K Officer / director change2026-06-26
- DEF 14A Proxy statement2026-05-11
- 10-Q Quarterly report2026-05-11
- 8-K Charter / bylaws change2026-05-04
- S-3/A Shelf registration (potential raise)2026-03-24
- 8-K Delisting notice2026-03-20
- S-3 Shelf registration (potential raise)2026-03-16
- 10-K Annual report2026-03-13
- 8-K Reg FD disclosure2026-02-26
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-222026-06-26open ↗SCHEDULE 13G/AFiling2026-05-20open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13GFiling2026-05-14open ↗SCHEDULE 13GFiling2026-05-14open ↗SCHEDULE 13G/AFiling2026-05-13open ↗ARSPeriod ending 2025-12-312026-05-11open ↗DEFA14AFiling2026-05-11open ↗DEF 14APeriod ending 2026-05-112026-05-11open ↗10-QPeriod ending 2026-03-312026-05-11open ↗8-KPeriod ending 2026-05-012026-05-04open ↗
Frequently asked
- Is Ernexa Therapeutics Inc. (ERNA) a buy?
- ERNA currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 755.9% YoY; but unprofitable (net margin -2419.9%).
- What is Ernexa Therapeutics Inc.'s quality score?
- ERNA scores 47.15686274509803/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0000748592, latest 10-Q filed 2026-05-11) · EODHD · as of 6/26/2026, 7:49:39 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.